DCL B Prox10 Anti-Blemish Wash
GMP Deviations
11,818 recalls · Class II, newest first
GMP Deviations
GMP Deviations
Presence of particulate matter in solution - black and transparent particles
CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer)
CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer)
An extraneous peak was observed for dissolution testing.
An extraneous peak was observed for dissolution testing.
An extraneous peak was observed for dissolution testing.
CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Discoloration.
CGMP Deviations: Detection of N-nitrosodimethylamine (NDMA) impurity in finished drug product.
CGMP deviations; repackaged product was recalled by the manufacturer because it was manufactured under the same conditions as products found to be sub-potent.
Defective Delivery System: Sustained trend of failure to dispense complaints.
cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.
cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.
cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.
Failed Stability Specifications: Below specification result for buprenorphine release rate.
CGMP Deviations
CGMP Deviations: Product manufactured in a facility where methanol was found in other distributed lots of product.
Marketed without an Approved NDA/ANDA.
CGMP Deviations
CGMP Deviations
CGMP Deviations
CGMP Deviations